Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01999192 · ClinicalTrials.gov registry record · Phase 2
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis
A Phase 2 study, sponsored by Biotest.
- Terminated
- Registry status
- Phase 2
- Development phase
- 321
- Enrollment target
NCT01999192 is a Phase 2 study that was terminated before completion, run by Biotest. The registered enrollment target is 321 participants.
The verdict
NCT01999192, a Phase 2 study, was terminated before completion, sponsored by Biotest.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 321 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy and safety of three different Tregalizumab doses in combination with Methotrexate (MTX) in subjects who have active rheumatoid arthritis and an inadequate response to MTX alone. The overall study duration is 24 weeks followed by a 24 week extension phase.
Interventions
- DRUG Placebo
- DRUG Tregalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 321 participants |
| Start Date | 2013-10 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01999192
The ClinicalTrials.gov registry entry for NCT01999192 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 321 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biotest, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01999192 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01999192 about?
NCT01999192 is a clinical study titled "Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis". The purpose of this study is to determine the efficacy and safety of three different Tregalizumab doses in combination with Methotrexate (MTX) in subjects who have active rheumatoid arthritis and an inadequate response to MTX alone. The overall study duration is 24 weeks followed by a 24 week exten...
What is the current status of trial NCT01999192?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 321 participants. The study started on 2013-10. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01999192?
The interventions under investigation include: Placebo (DRUG), Tregalizumab (DRUG).
Who is sponsoring clinical trial NCT01999192?
This trial is sponsored by Biotest, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.